Alnylam Pharmaceuticals, Inc. (ALNY) earnings: date, estimates, results and stock reactions
Next earnings: Q4 FY2026 on 2027-02-11 (expected, before the open). EPS estimate 1.73, revenue estimate 1.52B.
Over the last 12 reports the stock moved 10.1% on average (either way), rising 3 times and falling 9. EPS beat estimates 9 of 12 times; revenue 9 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-29 | 16.26 | 1.66 | +879.5% | 1.46B | 1.43B | -29.0% |
| Q2 FY2026 | 2026-07-30 | 1.21 | 1.63 | -25.8% | 1.29B | 1.32B | -28.3% |
| Q1 FY2026 | 2026-04-30 | 1.51 | 0.87 | +73.2% | 1.17B | 1.12B | -1.7% |
| Q4 FY2025 | 2026-02-12 | 0.82 | 1.16 | -29.3% | 1.10B | 1.15B | -2.4% |
| Q3 FY2025 | 2025-10-30 | 1.84 | 0.56 | +228.0% | 1.25B | 959.4M | -5.3% |
| Q2 FY2025 | 2025-07-31 | -0.51 | -0.54 | +6.2% | 773.7M | 662.9M | +18.2% |
| Q1 FY2025 | 2025-05-01 | -0.44 | -0.89 | +50.6% | 594.2M | 585.1M | -1.5% |
| Q4 FY2024 | 2025-02-13 | -0.65 | -0.62 | -4.8% | 593.2M | 582.6M | -3.6% |